Overview
- The new Maximum Fair Prices apply to widely used Part D medicines that accounted for about $42.5 billion, or roughly 15% of 2024 Part D spending, used by an estimated 5.3 million enrollees.
- Semaglutide products Ozempic, Rybelsus and Wegovy received negotiated monthly prices around $274 for common doses, with Wegovy’s highest dose about $385.
- CMS estimates Part D enrollees will save about $685 million out of pocket in 2027, though individual savings vary because negotiated amounts reflect what Medicare pays rather than a patient’s final pharmacy charge.
- The negotiated prices differ from the administration’s separate voluntary most‑favored‑nation deals, including a reported $245 monthly price for GLP‑1s that could start earlier and operate under distinct terms.
- Officials cite varying benchmarks for savings: CMS pegs gross program savings near $12 billion (about 44%), while another administration estimate describes $8.5 billion, or 36%, using a prior‑year baseline; the 2027 cuts bring the total negotiated drugs to 25, with more rounds ahead.